Benralizumab: First New Asthma Treatment in 50 Years Reduces Need for Further Treatment by 30%

Nov 28, 2024, 05:44 AM

A significant advancement in asthma and COPD treatment has emerged with the development of a new drug, benralizumab, which has shown to be more effective than traditional steroid tablets during acute attacks. This monoclonal antibody, targeting interleukin-5 receptor-α, was tested in a double-blind, double-dummy, active placebo-controlled randomized trial by King's College London. The study, published in The Lancet Respiratory Medicine, found that benralizumab reduced the need for further treatment by 30% compared to steroids. This breakthrough is being hailed as a 'game-changer' by doctors and patients, marking the first new treatment for asthma attacks in over 50 years.